Thrombolysis and surgical embolectomy are superior to anticoagulation, with thrombolysis possibly offering a modest survival benefit.
For special patient populations, such as the elderly and patients with limited performance status (PS), treatment with single-agent chemotherapy results in modest survival benefits and combination chemotherapy may be appropriate for some of these patients.
Unfortunately, current treatments for metastatic AIPC have demonstrated only modest survival advantages [7].
In our current and prior work, we have reported only a modest survival benefit when the lysate is delivered 24 h after infection.
At 17 days, well after the DosR regulon is induced [27] and bacteriostasis is firmly established, the dosR mutant showed a modest survival defect (Figure 1b).
In the Wayne model, neither the modest survival defect of the DosR mutant nor the cessation of replication aligns with the timing of DosR regulon induction [27].
However, the modest survival benefit associated with isolated CD86 blockade/deletion suggests that some of these protective effects may be modulated by CD80 as well.
In adult glioblastoma, introduction of combined chemoradiotherapy of concomitant and adjuvant temozolomide (TMZ) and radiotherapy has provided a modest survival benefit [5], particularly in patients with an epigenetically silenced O6-methylguanine-DNA-methyltransferase (MGMT) gene [6].
Current chemotherapy regimens have modest survival benefit.
However, chemotherapy in advanced disease confers only modest survival advantage and symptoms palliation.
Docetaxel is the first-line chemotherapy for CRPC, providing modest survival benefits [ 9– 11].
